Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Pörssitiedote

Mentice Secures $912,200 USD Order for Simulation Solution Services from a Top 20 Global MedTech company.

Mentice
Lataa tiedote

Mentice (publ), Gothenburg, a globally recognized leader in simulation solutions for image-guided interventional therapies, announced today that it has secured a significant order from a top 20 global Med Tech company, a long-standing customer of Mentice.

The order includes the delivery of simulation systems as part of a two-year service agreement to support physician and internal personnel training for structural heart therapies. The systems will facilitate technical and procedural training, addressing the clinical need for physician proficiency in advanced therapies to support improved patient outcomes. The agreement also includes a renewed software license to optimize the training platform.

Structural heart therapies, such as left atrial appendage occlusion, are essential for addressing stroke prevention in atrial fibrillation (AF) patients who are unsuitable for long-term anticoagulation. AF, a condition that affects over 59.7 million patients globally[1], significantly increases the risk of stroke and other cardiovascular complications, emphasizing the need for standardized physician training to ensure safe adoption. With the structural heart market experiencing rapid growth, the demand for effective therapies and training solutions continues to rise[2].

Göran Malmberg, CEO of Mentice, commented, "This order highlights the continued need for innovative training solutions to support the adoption of life-saving advanced structural heart therapies. We are proud to strengthen our collaboration with this leading company in the MedTech field, helping physicians deliver safer, more effective patient care and addressing the need of a rapidly growing market."


The order will be accounted for in the order book for the business area of the Medical Device Industry during the fourth quarter of 2024, with the services deliveries during the coming calendar years.


References:
[1] heart.bmj.com
[2] https://www.grandviewresearch.com/industry-analysis/structural-heart-devices-market

Mentice definition of a Top 20 Medical Technology company can be found here: https://www.beckershospitalreview.com/innovation/100-largest-medtech-companies.html.


For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: goran.malmberg@mentice.com
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22

About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB

This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-12-12 11:05 CET.

Attachments
Mentice Secures $912,200 USD Order for Simulation Solution Services from a Top 20 Global MedTech company.

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.